Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.
How OnabotulinumtoxinA “Revolutionized” Treatment of Urologic Conditions
Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Melissa R. Kaufman, MD, PhD, FACS, discusses the significance of onabotulinumtoxinA treatment in patients with overactive bladder. Dr. Kaufman is a Professor of urology, Patricia and Rodes Hart Endowed Chair of Urologic Surgery, and Chief of Reconstructive Urology and Pelvic Health at Vanderbilt University Medical Center, Nashville, Tennessee. Read more.
Source: Urology Times, February 16, 2022
EvidenceNOW: Managing Urinary Incontinence
In February 2022, AHRQ launched the Improving Nonsurgical Treatment of Urinary Incontinence among Women in Primary Care (INTUIT-PC). The initiative builds on AHRQ’s EvidenceNOW Model of external support to help primary care practices implement patient-centered outcomes research (PCOR) on effective nonsurgical interventions for UI such as behavioral approaches, medications, and neuromodulation. The initiative will help close the gap between evidence and primary care practice in care for UI in women. Read more.
Source: U.S. Agency for Healthcare Research and Quality, February 2022
New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary Incontinence
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today highlighted the publication of a new study that provides updated estimates of urinary incontinence (UI) prevalence in the U.S. The study, titled “Updated Prevalence of Urinary Incontinence in Women: 2015-2018 National Population-Based Survey Data,” was published in the peer-reviewed journal Female Pelvic Medicine & Reconstructive Surgery, the official journal of the American Urogynecologic Society (AUGS). Study authors at the University of Wisconsin School of Medicine and Public Health utilized publicly available data from the 2015-2018 National Health and Nutrition Examination Survey (NHANES) sample and included over 5,000 women who completed mobile examinations and computer-assisted personal interviews with standardized UI questions. Read more.
Source: Business Wire, January 25, 2022
Caldera Medical Announces FDA Clearance for New Desara® TVez for Stress Urinary Incontinence
Caldera Medical, a medical device company that develops best-in-class surgical products for the treatment of Stress Urinary Incontinence, Pelvic Organ Prolapse, and Polyps announced the launch of Desara® TVez, an expansion to their Desara® Family of products. Caldera Medical, a medical device company that develops best-in-class surgical products for the treatment of Stress Urinary Incontinence, Pelvic Organ Prolapse, and Polyps announced the launch of Desara® TVez, an expansion to their Desara® Family of products. Read more.
Source: Business Wire, December 2, 2021
Individual Pessaries For More Successful Treatment Of Stress Incontinence Through 3D Printing
Simply Standing up, doing sports, or just laughing, it’s extremely unpleasant whenever urine suddenly leaks uncontrollably. Colloquially referred to as a ‘weak bladder’, it’s known as Stress Urinary Incontinence in medical terms. Although about one in three women suffers from uncontrolled urine leakage, incontinence is still taboo. Initially merely a physical problem, it also quickly weighs on the soul. For fear of unpleasant situations, those affected often withdraw and avoid social activities with families and friends. 3D printed pessaries may relieve the burden. Read more.
Source: The Science Times, November 14, 2021
Let’s talk: Post-acute rehab patients need to be looped in about incontinence care, study finds
Post-acute care nurses are right on target with continence assessment and management, a new study finds. But their patients are largely unaware of these activities and think they’re going it alone, investigators say. The researchers conducted interviews with 10 nursing staff and 10 patients in two geriatric units of a rehabilitation hospital. Perhaps not surprisingly, nurses and patients had very different experiences of incontinence care. Read more.
Source: Urology Times, November 12, 2021
Study Finds Vibegron Has No Adverse Ambulatory Effects in Patients with OAB
It is important for clinicians to perform ambulatory blood pressure monitoring (ABPM) for patients taking new prescribed medications, as they may affect blood pressure or heart rate in detrimental ways. It is especially important to monitor patients with overactive bladder (OAB), as this group has an increasing abundance of novel medicines available to them. In a recent study presented at the 2021 American Urological Association Annual Meeting,¹ Michael A. Weber, MD, and co-authors assessed the blood pressure and heart rate profiles of the beta 3 adrenergic receptor agonist vibegron (Gemtesa) in treating patients with OAB. Read more.
Source: Urology Times, November 5 2021